Hoffmann-La Roche reports positive trial results for obesity drug enicepatide
What happened
Hoffmann-La Roche reported that its experimental obesity shot, enicepatide, reduced body weight by 15.5% and lowered HbA1c by 2.65% in Type 2 diabetes patients after 48 weeks. The drug, which is being developed as a once-weekly shot, is designed to activate GLP-1 and GIP hormones.
From swissinfo.ch
Why it matters
The results are considered competitive against rival drugs in Phase 3 trials, positioning Hoffmann-La Roche to compete in the global weight-loss drug market, which is estimated to reach $150 billion. Analysts cautioned that detailed placebo-adjusted data and replication in Phase 3 trials are needed to confirm the benefit.
Appetite-suppressing drugs are creating a new product market, leading to investor concern regarding the sector.
From swissinfo.ch
Who's involved
- Hoffmann-La RocheDeveloper of enicepatide, an experimental obesity drug
- Novo NordiskDirect competitor to Hoffmann-La Roche in the global obesity drug market
- Eli Lilly and CompanyCompetitor whose drug, Zepbound, is referenced in the market
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Novo NordiskSpeculative
Novo Nordisk could face increased competition in the global obesity drug market, potentially affecting future sales.
- Hoffmann-La RocheSpeculative
Hoffmann-La Roche could see increased investment and market valuation due to successful trial data for enicepatide.
How it developed
Newest first. Tap a step to see who reported it.- Roche reported positive results from enicepatide trials, showing it reduces HbA1c and weight in Type 2 diabetes.Sub-event
Roche and Novo Nordisk are competing in the global obesity drug market, reflected by stock trading in Zurich.1 source
Keep exploring
The entities involved
-
Hoffmann-La Roche
Swiss healthcare company
-
Novo Nordisk
Danish pharmaceutical company